Saturday, April 30, 2022 4:09:16 PM
Deputy Director and Senior Investigator, Lady Davis Institute
Minda de Gunzburg Professor of Oncology, McGill University
Director, Segal Cancer Centre, Jewish General Hospital
Director, McGill Centre for Translational Research in Cancer, Lady Davis Institute
Dr. Batist's Publications Indexed on PubMed
Dr. Gerald Batist was Chairman of the Department of Oncology, McGill University from 2001 until 2011. He is Director of the McGill Centre for Translational Research in Cancer (MCTRC), which was established to stimulate rapid translation of new discoveries in the research laboratory into clinical benefits for patients. A major award from the Canada Foundation for Innovation allowed for the MCTRC to be expanded to create the Montreal Centre for Experimental Therapeutics in Cancer (MCETC), now a major component of the Segal Cancer Centre at the Jewish General Hospital, which also serves as the Experimental Therapeutics Axis of the Réseau de recherche sur le cancer of the Fonds de la recherche en santé du Québec (FRSQ). He is also Director of the Segal Cancer Centre.
In 2007, together with Dr. Luc Bélanger, Director of the Centre de recherche en cancérologie de l’Université Laval at l’ Hôtel Dieu de Quebec (CHUQ), Dr. Batist co-founded the Quebec – Clinical Research Organization in Cancer (Q-CROC), which focuses on biomarker-driven clinical trials and therapeutic resistance. It is also active in oncology care. Q-CROC operates as a network that brings together basic and clinician researchers, oncologists, surgeons and pathologists, among others. Its firm intention is to establish a province-wide translational and clinical research infrastructure in oncology.
Dr. Batist was born in Montreal. After beginning his university studies in New York City, he returned to attend medical school at McGill University. This was followed by post-doctoral training in New York, Boston, and, finally, at the National Cancer Institute in Washington, where he trained in medical oncology and molecular pharmacology.
Dr. Batist’s research programs are in novel therapeutics, and he’s made significant contributions to the development of new cancer treatments. In his capacity as Chairman of Oncology at McGill, he has nurtured the development of a number of multidisciplinary programs that have been highly innovative and are among the first of their kind in Canada. He leads a highly successful laboratory and clinical research program, which has been credited with over 180 scientific publications and a number of book chapters. He has trained many scientists and clinical oncologists, and also practices medical oncology.
Recent SBFM News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:05:31 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 03/05/2024 09:37:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:05:35 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/23/2024 09:03:01 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/21/2024 09:28:39 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 02/21/2024 01:24:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 10:01:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 04:39:32 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:53:03 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/14/2024 04:18:31 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/13/2024 05:15:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 09:05:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 02:04:50 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/09/2024 10:17:56 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/01/2024 09:17:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 05:38:24 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/08/2024 01:10:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:59:51 PM
- Sunshine Biopharma Moves Principal Office to New York City • GlobeNewswire Inc. • 12/04/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 02:00:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:00:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 04:18:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/20/2023 05:06:33 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/19/2023 04:10:36 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM